Martin Christian Michel

List of Publications by Year
in descending order

295	12,183	31976	37204
papers	citations	53 h-index	96 g-index

319	319	319	11420
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	EAU Guidelines on the Treatment and Follow-up of Non-neurogenic Male Lower Urinary Tract Symptoms Including Benign Prostatic Obstruction. European Urology, 2013, 64, 118-140.	1.9	990
2	THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G proteinâ€coupled receptors. British Journal of Pharmacology, 2019, 176, S21-S141.	5.4	519
3	The Molecular Basis for the Pharmacokinetics and Pharmacodynamics of Curcumin and Its Metabolites in Relation to Cancer. Pharmacological Reviews, 2014, 66, 222-307.	16.0	418
4	Î±₁â€; Î±₂â€•and Î²â€adrenoceptors in the urinary bladder, urethra and prostate. British Journal of Pharmacology, 2006, 147, S88-119.	5.4	386
5	THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G proteinâ€coupled receptors. British Journal of Pharmacology, 2021, 178, S27-S156.	5.4	337
6	How reliable are G-protein-coupled receptor antibodies?. Naunyn-Schmiedeberg's Archives of Pharmacology, 2009, 379, 385-388.	3.0	264
7	A Systematic Comparison of the Properties of Clinically Used Angiotensin II Type 1 Receptor Antagonists. Pharmacological Reviews, 2013, 65, 809-848.	16.0	233
8	A Contemporary Assessment of Nocturia: Definition, Epidemiology, Pathophysiology, and Managementâ€”a Systematic Review and Meta-analysis. European Urology, 2012, 62, 877-890.	1.9	231
9	Mirabegron in overactive bladder: A review of efficacy, safety, and tolerability. Neurourology and Urodynamics, 2014, 33, 17-30.	1.5	228
10	Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence. Current Opinion in Urology, 2009, 19, 380-394.	1.8	161
11	EFFECT OF DIABETES ON LOWER URINARY TRACT SYMPTOMS IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA. Journal of Urology, 2000, 163, 1725-1729.	0.4	154
12	Signal Transduction Underlying Carbachol-Induced Contraction of Human Urinary Bladder. Journal of Pharmacology and Experimental Therapeutics, 2004, 309, 1148-1153.	2.5	152
13	A comprehensive nonâ€clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder. British Journal of Clinical Pharmacology, 2011, 72, 235-246.	2.4	152
14	Impact of GPCRs in clinical medicine: Monogenic diseases, genetic variants and drug targets. Biochimica Et Biophysica Acta - Biomembranes, 2007, 1768, 994-1005.	2.6	151
15	Is the use of parasympathomimetics for treating an underactive urinary bladder evidenceâ€based?. BJU International, 2007, 99, 749-752.	2.5	140
16	Signal transduction underlying the control of urinary bladder smooth muscle tone by muscarinic receptors and Î²-adrenoceptors. Naunyn-Schmiedeberg's Archives of Pharmacology, 2008, 377, 449-462.	3.0	139
17	Lack of specificity of commercially available antisera against muscarinergic and adrenergic receptors. Naunyn-Schmiedeberg's Archives of Pharmacology, 2009, 379, 397-402.	3.0	131
18	Effects of ??1-Adrenoceptor Antagonists on Male Sexual Function. Drugs, 2006, 66, 287-301.	10.9	119

#	Article	IF	Citations
19	Elevation of plasma neuropeptide Y levels in congestive heart failure. American Journal of Medicine, 1989, 86, 43-48.	1.5	117
20	Nerve growth factor in bladder dysfunction: Contributing factor, biomarker, and therapeutic target. Neurourology and Urodynamics, 2011, 30, 1227-1241.	1.5	115
21	Small and intermediate conductance Ca 2+ -activated K + channels confer distinctive patterns of distribution in human tissues and differential cellular localisation in the colon and corpus cavernosum. Naunyn-Schmiedeberg's Archives of Pharmacology, 2004, 369, 602-615.	3.0	112
22	Mitogen-activated protein kinases in the heart. Naunyn-Schmiedeberg's Archives of Pharmacology, 2001, 363, 245-266.	3.0	109
23	ASSOCIATION OF HYPERTENSION WITH SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA. Journal of Urology, 2004, 172, 1390-1393.	0.4	108
24	Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome. Expert Opinion on Pharmacotherapy, 2008, 9, 1787-1796.	1.8	105
25	TAMSULOSIN TREATMENT OF 19,365 PATIENTS WITH LOWER URINARY TRACT SYMPTOMS: DOES CO-MORBIDITY ALTER TOLERABILITY?. Journal of Urology, 1998, 160, 784-791.	0.4	99
26	A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer. Naunyn-Schmiedeberg's Archives of Pharmacology, 2014, 387, 505-521.	3.0	97
27	A Multicenter, Double-blind, Randomized, Placebo-controlled Trial of the Î²3-Adrenoceptor Agonist Solabegron for Overactive Bladder. European Urology, 2012, 62, 834-840.	1.9	96
28	Sphingosine-1-phosphate and sphingosylphosphorylcholine constrict renal and mesenteric microvessels in vitro. British Journal of Pharmacology, 2000, 130, 1871-1877.	5.4	95
29	Does Gender or Age Affect the Efficacy and Safety of Tolterodine?. Journal of Urology, 2002, 168, 1027-1031.	0.4	94
30	Rho kinase: a target for treating urinary bladder dysfunction?. Trends in Pharmacological Sciences, 2006, 27, 492-497.	8.7	90
31	Tools to study Î²3-adrenoceptors. Naunyn-Schmiedeberg's Archives of Pharmacology, 2007, 374, 385-398.	3.0	90
32	Saw palmetto extracts potently and noncompetitively inhibit human ?1-adrenoceptors in vitro. , 1999, 38, 208-215.		84
33	Spare Receptors for Î²-Adrenoceptor-Mediated Positive Inotropic Effects of Catecholamines in the Human Heart. Journal of Cardiovascular Pharmacology, 1992, 19, 222-232.	1.9	81
34	Prevalence and Physician Awareness of Symptoms of Urinary Bladder Dysfunction. European Urology, 2002, 41, 234-239.	1.9	81
35	Physiological and pathological regulation of the autonomic control of urinary bladder contractility. , 2008, 117, 297-312.		79
36	New Author Guidelines for Displaying Data and Reporting Data Analysis and Statistical Methods in Experimental Biology. Molecular Pharmacology, 2020, 97, 49-60.	2.3	79

#	Article	IF	Citations
37	Is Î±1D-adrenoreptor protein detactable in rat tissues?. Naunyn-Schmiedeberg's Archives of Pharmacology, 1997, 355, 438-446.	3.0	77
38	Signal Transduction Underlying Carbachol-Induced Contraction of Rat Urinary Bladder. I. Phospholipases and Ca²⁺Sources. Journal of Pharmacology and Experimental Therapeutics, 2004, 308, 47-53.	2.5	76
39	Biased Agonism in Drug Discoveryâ€"Is It Too Soon to Choose a Path?. Molecular Pharmacology, 2018, 93, 259-265.	2.3	76
40	Evidence Why Paroxetine Dose Escalation is Not Effective in Major Depressive Disorder: A Randomized Controlled Trial With Assessment of Serotonin Transporter Occupancy. Neuropsychopharmacology, 2009, 34, 999-1010.	5.4	73
41	The Odd Sibling: Features ofÎ²₃-Adrenoceptor Pharmacology. Molecular Pharmacology, 2014, 86, 479-484.	2.3	73
42	Pharmacological profile of Î²3-adrenoceptor agonists in clinical development for the treatment of overactive bladder syndrome. Naunyn-Schmiedeberg's Archives of Pharmacology, 2013, 386, 177-183.	3.0	71
43	Does Cyclic AMP Mediate Rat Urinary Bladder Relaxation by Isoproterenol?. Journal of Pharmacology and Experimental Therapeutics, 2005, 313, 260-267.	2.5	70
44	Cyclic AMP-dependent and Epac-mediated Activation of R-Ras by G Protein-coupled Receptors Leads to Phospholipase D Stimulation. Journal of Biological Chemistry, 2006, 281, 21837-21847.	3.4	68
45	Basic Mechanisms of Urgency: Preclinical and Clinical Evidence. European Urology, 2009, 56, 298-308.	1.9	66
46	How valid are animal models to evaluate treatments for pulmonary hypertension?. Naunyn-Schmiedeberg's Archives of Pharmacology, 2006, 373, 391-400.	3.0	64
47	Pitfalls in the normalization of real-time polymerase chain reaction data. Basic Research in Cardiology, 2007, 102, 195-197.	5.9	60
48	Opportunities and Challenges for Drug Development: Publicâ€"Private Partnerships, Adaptive Designs and Big Data. Frontiers in Pharmacology, 2016, 7, 461.	3.5	60
49	Comparison of the positive inotropic effects of serotonin, histamine, angiotensin II, endothelin and isoprenaline in the isolated human right atrium. Naunyn-Schmiedeberg's Archives of Pharmacology, 1993, 347, 347-352.	3.0	59
50	Gender comparison of muscarinic receptor expression and function in rat and human urinary bladder: differential regulation of M2 and M3 receptors?. Naunyn-Schmiedeberg's Archives of Pharmacology, 2003, 367, 524-531.	3.0	59
51	Decreased myometrial Î²-adrenoceptors in women receiving Î²2-adrenergic tocolytic therapy: Correlation with lymphocyte Î²-adrenoceptors. Clinical Pharmacology and Therapeutics, 1989, 45, 1-8.	4.7	58
52	Cholinergic Innervation and Muscarinic Receptors in the Human Prostate. European Urology, 2008, 54, 326-334.	1.9	58
53	Effects of gender, age and hypertension on Î²-adrenergic receptor function in rat urinary bladder. Naunyn-Schmiedeberg's Archives of Pharmacology, 2006, 373, 300-309.	3.0	56
54	The Pharmacokinetic Profile of Tamsulosin Oral Controlled Absorption System (OCASÂ®). European Urology Supplements, 2005, 4, 15-24.	0.1	55

#	Article	IF	Citations
55	Cardiovascular Safety and Overall Tolerability of Solifenacin in Routine??Clinical Use. Drug Safety, 2008, 31, 505-514.	3.2	55
56	The role of nocturia in the quality of life of men with lower urinary tract symptoms. BJU International, 2010, 105, 1141-1146.	2.5	55
57	Pharmacokinetics and Pharmacodynamics of Tamsulosin in its Modified-Release and Oral Controlled Absorption System Formulations. Clinical Pharmacokinetics, 2010, 49, 177-188.	3.5	55
58	Angiotensin II type 1 receptor antagonists in animal models of vascular, cardiac, metabolic and renal disease. , 2016, 164, 1-81.		55
59	Effects of ageing on muscarinic receptor subtypes and function in rat urinary bladder. Naunyn-Schmiedeberg's Archives of Pharmacology, 2005, 372, 71-78.	3.0	54
60	A comprehensive review of the pharmacodynamics of the SGLT2 inhibitor empagliflozin in animals and humans. Naunyn-Schmiedeberg's Archives of Pharmacology, 2015, 388, 801-816.	3.0	54
61	Radioligand binding studies of Î±₁â€adrenoceptor subtypes in rat heart. British Journal of Pharmacology, 1994, 111, 533-538.	5.4	53
62	Safety of Telmisartan in Patients with Arterial Hypertension. Drug Safety, 2004, 27, 335-344.	3.2	53
63	New Author Guidelines for Displaying Data and Reporting Data Analysis and Statistical Methods in Experimental Biology. Journal of Pharmacology and Experimental Therapeutics, 2020, 372, 136-147.	2.5	53
64	Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the cardiovascular system. BJU International, 2005, 95, 19-28.	2.5	52
65	Î²3-Adrenoceptor agonists for overactive bladder syndrome: Role of translational pharmacology in a repositioning clinical drug development project. , 2016, 159, 66-82.		52
66	Inhibition of synaptosomal high-affinity uptake of dopamine and serotonin by estrogen agonists and antagonists. Biochemical Pharmacology, 1987, 36, 3175-3180.	4.4	51
67	Nocturia: A nonâ€specific but important symptom of urological disease. International Journal of Urology, 2009, 16, 249-256.	1.0	50
68	Unexpected frequent hepatotoxicity of a prescription drug, flupirtine, marketed for about 30 years. British Journal of Clinical Pharmacology, 2012, 73, 821-825.	2.4	50
69	Receptor subtypes Y1 and Y5 are involved in the renal effects of neuropeptide Y. British Journal of Pharmacology, 1997, 120, 1335-1343.	5.4	49
70	A Comprehensive Review of the Pharmacodynamics, Pharmacokinetics, and Clinical Effects of the Neutral Endopeptidase Inhibitor Racecadotril. Frontiers in Pharmacology, 2012, 3, 93.	3.5	49
71	Î±1-Adrenoceptor Subtypes Differentially Couple to Growth Promotion and Inhibition in Chinese Hamster Ovary Cells. Biochemical and Biophysical Research Communications, 2000, 272, 906-911.	2.1	48
72	Radioreceptor assay analysis of tamsulosin and terazosin pharmacokinetics. British Journal of Clinical Pharmacology, 1998, 45, 49-55.	2.4	46

#	Article	IF	Citations
73	Comparison of three radioligands for the labelling of human Î²-adrenoceptor subtypes. Naunyn-Schmiedeberg's Archives of Pharmacology, 2006, 374, 99-105.	3.0	46
74	The pharmacological rationale for combining muscarinic receptor antagonists and Î²-adrenoceptor agonists in the treatment of airway and bladder disease. Current Opinion in Pharmacology, 2014, 16, 31-42.	3.5	45
75	TAMSULOSIN TREATMENT OF 19,365 PATIENTS WITH LOWER URINARY TRACT SYMPTOMS. Journal of Urology, 1998, 160, 784-791.	0.4	45
76	Muscarinic receptor subtypes in porcine detrusor: comparison with humans and regulation by bladder augmentation. Urological Research, 1998, 26, 149-154.	1.5	44
77	Treatment of the overactive bladder syndrome with muscarinic receptor antagonists - a matter of metabolites?. Naunyn-Schmiedeberg's Archives of Pharmacology, 2006, 374, 79-85.	3.0	44
78	Comparison of Symptom Severity and Treatment Response in Patients with Incontinent and Continent Overactive Bladder. European Urology, 2005, 48, 110-115.	1.9	43
79	The Î²₃â€adrenoceptor agonist mirabegron increases human atrial force through Î²₁â€adrenoceptors: an indirect mechanism?. British Journal of Pharmacology, 2017, 174, 2706-2715.	5.4	43
80	Sphingosine Kinaseâ€“Dependent Activation of Endothelial Nitric Oxide Synthase by Angiotensin II. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 2043-2048.	2.4	42
81	The effect of bladder outlet obstruction on Î±₁â€•and Î²â€adrenoceptor expression and function. Neurourology and Urodynamics, 2009, 28, 349-355.	1.5	42
82	Medical Expulsive Therapy for Distal Ureteral Stones. Drugs, 2009, 69, 677-692.	10.9	42
83	Safety and tolerability of Î²₃-adrenoceptor agonists in the treatment of overactive bladder syndrome â€“ insight from transcriptosome and experimental studies. Expert Opinion on Drug Safety, 2016, 15, 647-657.	2.4	42
84	Do gene polymorphisms alone or in combination affect the function of human Î²₃â€adrenoceptors?. British Journal of Pharmacology, 2009, 156, 127-134.	5.4	41
85	Cardiovascular and ocular safety of Î±₁-adrenoceptor antagonists in the treatment of male lower urinary tract symptoms. Expert Opinion on Drug Safety, 2014, 13, 1187-1197.	2.4	41
86	Systematic review of guidelines for internal validity in the design, conduct and analysis of preclinical biomedical experiments involving laboratory animalsSystematic review of guidelines for internal validity in the design, conduct and analysis of preclinical biomedical experiments involving laboratory animals. BMJ Open Science, 2020, 44, e100046.	1.7	40
87	Cyclic AMP counteracts mitogenâ€induced inositol phosphate generation and increases in intracellular Ca²⁺ concentrations in human lymphocytes. British Journal of Pharmacology, 1991, 103, 1288-1294.	5.4	39
88	Effect of pre-contraction on Î²-adrenoceptor-mediated relaxation of rat urinary bladder. World Journal of Urology, 2009, 27, 711-5.	2.2	39
89	The Forefront for Novel Therapeutic Agents Based on the Pathophysiology of Lower Urinary Tract Dysfunction: Î±-Blockers in the Treatment of Male Voiding Dysfunction â€" How Do They Work and Why Do They Differ in Tolerability?. Journal of Pharmacological Sciences, 2010, 112, 151-157.	2.5	39
90	Tissue functions mediated by Î²3-adrenoceptorsâ€"findings and challenges. Naunyn-Schmiedeberg's Archives of Pharmacology, 2010, 382, 103-108.	3.0	39

#	Article	IF	Citations
91	In vivo studies on the effects of Î±1-adrenoceptor antagonists on pupil diameter and urethral tone in rabbits. Naunyn-Schmiedeberg's Archives of Pharmacology, 2006, 372, 346-353.	3.0	37
92	Competition by monophenolic estrogens and catecholestrogens for high-affinity uptake of [3H](â^')-norepinephrine into synaptosomes from rat cerebral cortex and hypothalamus. Brain Research, 1983, 277, 163-168.	2.2	36
93	Tocolytic Therapy with Fenoterol Induces Selective Down-Regulation of Î²-Adrenergic Receptors in Human Myometrium¹. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 1235-1242.	3.6	36
94	Lysosphingolipid receptorâ€mediated diuresis and natriuresis in anaesthetized rats. British Journal of Pharmacology, 2001, 132, 1925-1933.	5.4	36
95	Role of muscarinic receptor antagonists in urgency and nocturia. BJU International, 2005, 96, 37-42.	2.5	36
96	Functional studies on Î±₁â€adrenoceptor subtypes mediating inotropic effects in rat right ventricle. British Journal of Pharmacology, 1994, 111, 539-546.	5.4	35
97	Specificity evaluation of antibodies against human Î²3-adrenoceptors. Naunyn-Schmiedeberg's Archives of Pharmacology, 2012, 385, 875-882.	3.0	35
98	A ROLE FOR MUSCARINIC RECEPTORS OR RHO-KINASE IN HYPERTENSION ASSOCIATED RAT BLADDER DYSFUNCTION?. Journal of Urology, 2005, 173, 2178-2181.	0.4	34
99	Ligand-Directed Signaling: 50 Ways to Find a Lover: Fig. 1.. Molecular Pharmacology, 2007, 72, 1097-1099.	2.3	34
100	Are there functional Î²₃â€adrenoceptors in the human heart?. British Journal of Pharmacology, 2011, 162, 817-822.	5.4	34
101	Expression profiling of Gâ€proteinâ€coupled receptors in human urothelium and related cell lines. BJU International, 2012, 110, E293-300.	2.5	34
102	Agonist high- and low-affinity states of dopamine D2 receptors: methods of detection and clinical implications. Naunyn-Schmiedeberg's Archives of Pharmacology, 2013, 386, 135-154.	3.0	34
103	Neuropeptide Y (NPY) receptors in HEL cells: comparison of binding and functional parameters for full and partial agonists and a nonâ€peptide antagonist. British Journal of Pharmacology, 1992, 105, 71-76.	5.4	33
104	Vascular effects of sphingolipids. Acta Paediatrica, International Journal of Paediatrics, 2007, 96, 44-48.	1.5	33
105	Î²₃â€Adrenoceptors in the normal and diseased urinary bladderâ€"What are the open questions?. British Journal of Pharmacology, 2019, 176, 2525-2538.	5.4	33
106	Differential calcium signalling by m2 and m3 muscarinic acetylcholine receptors in a single cell type. Naunyn-Schmiedeberg's Archives of Pharmacology, 1995, 352, 469-476.	3.0	32
107	Î²-Adrenergic Receptor Subtypes in the Urinary Tract. Handbook of Experimental Pharmacology, 2011, , 307-318.	1.8	32
108	Effects of strong CYP2D6 and 3A4 inhibitors, paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of tamsulosin. British Journal of Clinical Pharmacology, 2011, 72, 247-256.	2.4	32

#	Article	IF	Citations
109	Modulation of lower urinary tract smooth muscle contraction and relaxation by the urothelium. Naunyn-Schmiedeberg's Archives of Pharmacology, 2018, 391, 675-694.	3.0	32
110	Relationships among symptoms, bother, and treatment satisfaction in overactive bladder patients. Neurourology and Urodynamics, 2007, 26, 190-195.	1.5	31
111	Does Phospholipase C Mediate Muscarinic Receptor-Induced Rat Urinary Bladder Contraction?. Journal of Pharmacology and Experimental Therapeutics, 2007, 322, 998-1002.	2.5	30
112	Do Î²-adrenoceptor agonists induce homologous or heterologous desensitization in rat urinary bladder?. Naunyn-Schmiedeberg's Archives of Pharmacology, 2014, 387, 215-224.	3.0	30
113	Treatment Satisfaction of Patients with Lower Urinary Tract Symptoms: Randomised Controlled Trials vs. Real Life Practice. European Urology, 2000, 38, 40-47.	1.9	29
114	A Benefit-Risk Assessment of Extended-Release Oxybutynin. Drug Safety, 2002, 25, 867-876.	3.2	29
115	Cardiovascular Safety of the Oral Controlled Absorption System (OCAS) Formulation of Tamsulosin Compared to the Modified Release (MR) Formulation. European Urology Supplements, 2005, 4, 53-60.	0.1	29
116	Muscarinic receptor antagonists for overactive bladder treatment: does one fit all?. Current Opinion in Urology, 2009, 19, 13-19.	1.8	29
117	Role of voiding and storage symptoms for the quality of life before and after treatment in men with voiding dysfunction. World Journal of Urology, 2010, 28, 3-8.	2.2	29
118	Î²-Adrenoceptor agonist effects in experimental models of bladder dysfunction. , 2011, 131, 40-49.		29
119	Lack of evidence that nebivolol is a Î²3-adrenoceptor agonist. European Journal of Pharmacology, 2011, 654, 86-91.	3.5	29
120	The Neuro-Urological Connection. European Urology Supplements, 2005, 4, 18-28.	0.1	28
121	Cardiovascular Safety of Tamsulosin Modified Release in the Fasted and Fed State in Elderly Healthy Subjects. European Urology Supplements, 2005, 4, 9-14.	0.1	28
122	Basic mechanisms of urgency: roles and benefits of pharmacotherapy. World Journal of Urology, 2009, 27, 705-9.	2.2	28
123	Functional investigation of Î²-adrenoceptors in human isolated detrusor focusing on the novel selective Î²3-adrenoceptor agonist KUC-7322. Naunyn-Schmiedeberg's Archives of Pharmacology, 2012, 385, 759-767.	3.0	28
124	A systematic review of urinary bladder hypertrophy in experimental diabetes: Part 2. Comparison of animal models and functional consequences. Neurourology and Urodynamics, 2018, 37, 2346-2360.	1.5	28
125	Prejunctional Neuropeptide Y Receptors in Human Kidney and Atrium. Journal of Cardiovascular Pharmacology, 1997, 29, 656-661.	1.9	28
126	Does gender or age affect the efficacy and safety of tolterodine?. Journal of Urology, 2002, 168, 1027-31.	0.4	28

#	Article	IF	Citations
127	Transient receptor potential vanilloid 1 mediates nerve growth factorâ€induced bladder hyperactivity and noxious input. BJU International, 2012, 110, E422-8.	2.5	27
128	Agonistâ€induced desensitisation of Î²₃â€adrenoceptors: Where, when, and how?. British Journal of Pharmacology, 2019, 176, 2539-2558.	5.4	26
129	DOES CONCOMITANT STRESS INCONTINENCE ALTER THE EFFICACY OF TOLTERODINE IN PATIENTS WITH OVERACTIVE BLADDER?. Journal of Urology, 2004, 172, 601-604.	0.4	25
130	Bradykinin modulates spontaneous nerve growth factor production and stretch-induced ATP release in human urothelium. Pharmacological Research, 2013, 70, 147-154.	7.1	25
131	Differential vascular Î± 1 â€adrenoceptor antagonism by tamsulosin and terazosin. British Journal of Clinical Pharmacology, 1999, 47, 67-74.	2.4	24
132	Nifedipine inhibits sphingosine-1-phosphate-induced renovascular contraction in vitro and in vivo. Naunyn-Schmiedeberg's Archives of Pharmacology, 2001, 364, 179-182.	3.0	24
133	Comparison of Vascular Î±1-Adrenoceptor Antagonism of Tamsulosin in Oral Controlled Absorption System (OCAS) and Modified Release (MR) Formulations. European Urology Supplements, 2005, 4, 45-52.	0.1	24
134	Different muscarinic receptor subtypes modulate proliferation of primary human detrusor smooth muscle cells via Akt/PI3K and map kinases. Pharmacological Research, 2013, 74, 1-6.	7.1	24
135	Do saw palmetto extracts block human?1-adrenoceptor subtypes in vivo?. Prostate, 2001, 46, 226-232.	2.3	23
136	Efficacy and safety of tamsulosin in the treatment of urological diseases. Expert Opinion on Pharmacotherapy, 2004, 5, 151-160.	1.8	23
137	The new radioligand [3H]-L 748,337 differentially labels human and rat Î²3-adrenoceptors. European Journal of Pharmacology, 2013, 720, 124-130.	3.5	23
138	Lower Urinary Tract Symptoms: Whatâ€™s New in Medical Treatment?. European Urology Focus, 2018, 4, 17-24.	3.1	23
139	Human Urinary Bladder Strip Relaxation by the Î²-Adrenoceptor Agonist Isoprenaline: Methodological Considerations and Effects of Gender and Age. Frontiers in Pharmacology, 2011, 2, 11.	3.5	22
140	Are blood vessels a target to treat lower urinary tract dysfunction?. Naunyn-Schmiedeberg's Archives of Pharmacology, 2015, 388, 687-694.	3.0	22
141	A systematic review of urinary bladder hypertrophy in experimental diabetes: Part I. Streptozotocinâ€induced rat models. Neurourology and Urodynamics, 2018, 37, 1212-1219.	1.5	22
142	Muscarinic type-1 receptors contribute to I K,ACh in human atrial cardiomyocytes and are upregulated in patients with chronic atrial fibrillation. International Journal of Cardiology, 2018, 255, 61-68.	1.7	22
143	Cognitive and mood side effects of lower urinary tract medication. Expert Opinion on Drug Safety, 2019, 18, 915-923.	2.4	22
144	Hunting for the highâ€affinity state of Gâ€proteinâ€coupled receptors with agonist tracers: Theoretical and practical considerations for positron emission tomography imaging. Medicinal Research Reviews, 2019, 39, 1014-1052.	10.5	22

#	Article	IF	Citations
145	Efficacy of propiverine ER with or without Î±-blockers related to maximum urinary flow rate in adult men with OAB: results of a 12-week, multicenter, non-interventional study. World Journal of Urology, 2011, 29, 217-223.	2.2	21
146	The Î±_{1B}â€adrenoceptor subtype mediates adrenergic vasoconstriction in mouse retinal arterioles with damaged endothelium. British Journal of Pharmacology, 2014, 171, 3858-3867.	5.4	21
147	Therapeutic Modulation of Urinary Bladder Function: Multiple Targets at Multiple Levels. Annual Review of Pharmacology and Toxicology, 2015, 55, 269-287.	9.4	21
148	Cardiac Î²₃â€adrenoceptorsâ€"A role in human pathophysiology?. British Journal of Pharmacology, 2019, 176, 2482-2495.	5.4	21
149	Comparison of the Cardiovascular Effects of Tamsulosin Oral Controlled Absorption System (OCASÂ®) and Alfuzosin Prolonged Release (XL). European Urology, 2006, 49, 501-509.	1.9	20
150	Therapeutic targets for overactive bladder other than smooth muscle. Expert Opinion on Therapeutic Targets, 2015, 19, 687-705.	3.4	20
151	Selectivity of pharmacological tools: implications for use in cell physiology. A Review in the Theme: Cell Signaling: Proteins, Pathways and Mechanisms. American Journal of Physiology - Cell Physiology, 2015, 308, C505-C520.	4.6	20
152	Muscarinic receptors stimulate cell proliferation in the human urothelium-derived cell line UROtsa. Pharmacological Research, 2011, 64, 420-425.	7.1	19
153	Muscarinic receptor subtypes and signalling involved in the attenuation of isoprenaline-induced rat urinary bladder relaxation. Naunyn-Schmiedeberg's Archives of Pharmacology, 2011, 384, 555-563.	3.0	19
154	21st century headache: mapping new territory. Journal of Headache and Pain, 2021, 22, 19.	6.0	19
155	Limited signal transduction repertoire of human Y5 neuropeptide Y receptors expressed in HEC-1B cells. Peptides, 2001, 22, 387-394.	2.4	18
156	Receptor gene polymorphisms: lessons on functional relevance from the Î²1 -adrenoceptor. British Journal of Pharmacology, 2003, 138, 279-282.	5.4	18
157	Similarities and differences in the autonomic control of airway and urinary bladder smooth muscle. Naunyn-Schmiedeberg's Archives of Pharmacology, 2008, 378, 217-224.	3.0	18
158	Î²3-Adrenoceptor-mediated relaxation of rat and human urinary bladder: roles of BKCa channels and Rho kinase. Naunyn-Schmiedeberg's Archives of Pharmacology, 2015, 388, 749-759.	3.0	18
159	Normalization of organ bath contraction data for tissue specimen size: does one approach fit all?. Naunyn-Schmiedeberg's Archives of Pharmacology, 2020, 393, 243-251.	3.0	18
160	Duloxetine in the Treatment of Stress Urinary Incontinence. Women's Health, 2005, 1, 345-358.	1.5	17
161	Rat Î²3-adrenoceptor protein expression: antibody validation and distribution in rat gastrointestinal and urogenital tissues. Naunyn-Schmiedeberg's Archives of Pharmacology, 2014, 387, 1117-1127.	3.0	17
162	Rapid desensitization of adrenalineâ€•and neuropeptide Yâ€stimulated Ca²⁺ mobilization in HELâ€cells. British Journal of Pharmacology, 1994, 112, 499-504.	5.4	16

#	Article	IF	Citations
163	An Extract From the Bark of Aspidosperma Quebracho Blanco Binds to Human Penile Î±-Adrenoceptors. Journal of Urology, 2002, 168, 160-163.	0.4	16
164	Does the Number of Previous Vaginal Deliveries Affect Overactive Bladder Symptoms and their Response to Treatment?. LUTS: Lower Urinary Tract Symptoms, 2009, 1, 82-87.	1.3	16
165	Agonist-induced desensitization of human Î²3-adrenoceptors expressed in human embryonic kidney cells. Naunyn-Schmiedeberg's Archives of Pharmacology, 2013, 386, 843-851.	3.0	16
166	A quantitative analysis of antagonism and inverse agonism at wild-type and constitutively active hamster Î± 1B -adrenoceptors. Naunyn-Schmiedeberg's Archives of Pharmacology, 2001, 363, 34-39.	3.0	15
167	Modulation of noradrenaline-induced microvascular constriction by protein kinase inhibitors. Naunyn-Schmiedeberg's Archives of Pharmacology, 2001, 363, 57-65.	3.0	15
168	S1P receptor signalling and RGS proteins; expression and function in vascular smooth muscle cells and transfected CHO cells. European Journal of Pharmacology, 2008, 600, 1-9.	3.5	15
169	Are polymorphisms of the Î²₃â€adrenoceptor gene associated with an altered bladder function?. Neurourology and Urodynamics, 2013, 32, 276-280.	1.5	15
170	Dynamic bias and its implications for GPCR drug discovery. Nature Reviews Drug Discovery, 2014, 13, 869-869.	46.4	15
171	Factors associated with efficacy of an ibuprofen/pseudoephedrine combination drug in pharmacy customersÂwith common cold symptoms. International Journal of Clinical Practice, 2017, 71, e12907.	1.7	15
172	Where will the next generation of medical treatments for overactive bladder syndrome come from?. International Journal of Urology, 2020, 27, 289-294.	1.0	15
173	NPY and carbachol raise Ca2+ in SK-N-MC cells by three different mechanisms. Naunyn-Schmiedeberg's Archives of Pharmacology, 1992, 345, 370-4.	3.0	14
174	The muscarinic receptor antagonist propiverine exhibits Î±1-adrenoceptor antagonism in human prostate and porcine trigonum. World Journal of Urology, 2011, 29, 149-155.	2.2	14
175	Regulation of GAPDH expression by treatment with the Î²-adrenoceptor agonist isoprenalineâ€"is GADPH a suitable loading control in immunoblot experiments?. Naunyn-Schmiedeberg's Archives of Pharmacology, 2015, 388, 1119-1120.	3.0	14
176	Characterization of differential patient profiles and therapeutic responses of pharmacy customers for four ambroxol formulations. BMC Pharmacology & Toxicology, 2018, 19, 40.	2.4	14
177	A Systematic Review of Inverse Agonism at Adrenoceptor Subtypes. Cells, 2020, 9, 1923.	4.1	14
178	Neuropeptide Y Lowers Blood Glucose in Anaesthetized Rats via a Y5Receptor Subtype. Endocrinology, 1998, 139, 3018-3021.	2.8	13
179	Differential agonist-induced regulation of human M2 and M3 muscarinic receptors. Biochemical Pharmacology, 2003, 66, 2099-2105.	4.4	13
180	Understanding Dose Titration: Overactive Bladder Treatment With Fesoterodine as an Example. European Urology Supplements, 2011, 10, 8-13.	0.1	13

#	Article	IF	Citations
181	Bradykinin Contracts Rat Urinary Bladder Largely Independently of Phospholipase C. Journal of Pharmacology and Experimental Therapeutics, 2014, 348, 25-31.	2.5	13
182	Do overactive bladder symptoms and their treatmentâ€associated changes exhibit a normal distribution? Implications for analysis and reporting. Neurourology and Urodynamics, 2020, 39, 754-761.	1.5	13
183	Adrenoceptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide To Pharmacology CITE, 2019, 2019, .	0.2	13
184	Î±1-adrenoceptor activity of Î²-adrenoceptor ligands â€“ An expected drug property with limited clinical relevance. European Journal of Pharmacology, 2020, 889, 173632.	3.5	12
185	A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021. Naunyn-Schmiedeberg's Archives of Pharmacology, 2022, 395, 867-885.	3.0	12
186	Neuropeptide Y enhances potassium excretion by mechanisms distinct from those controlling sodium excretion. Canadian Journal of Physiology and Pharmacology, 2000, 78, 93-99.	1.4	11
187	Which singleâ€item measures of overactive bladder symptom treatment correlate best with patient satisfaction?. Neurourology and Urodynamics, 2011, 30, 510-514.	1.5	11
188	How Î²₃â€adrenoceptorâ€selective is mirabegron?. British Journal of Pharmacology, 2016, 173, 429-430.	5.4	11
189	Impact of early vs. delayed initiation of dutasteride/tamsulosin combination therapy on the risk of acute urinary retention or BPH-related surgery in LUTS/BPH patients with moderate-to-severe symptoms at risk of disease progression. World Journal of Urology, 2021, 39, 2635-2643.	2.2	11
190	Desirable properties of Î²3-adrenoceptor agonists: Implications for the selection of drug development candidates. European Journal of Pharmacology, 2011, 657, 1-3.	3.5	10
191	Commentary on the BJP's new statistical reporting guidelines. British Journal of Pharmacology, 2018, 175, 3636-3637.	5.4	10
192	Urinary Bladder Weight and Function in a Rat Model of Mild Hyperglycemia and Its Treatment With Dapagliflozin. Frontiers in Pharmacology, 2019, 10, 911.	3.5	10
193	Cardiac and Vascular Î±1-Adrenoceptors in Congestive Heart Failure: A Systematic Review. Cells, 2020, 9, 2412.	4.1	10
194	Polymorphisms in Human Muscarinic Receptor Subtype Genes. Handbook of Experimental Pharmacology, 2012, , 49-59.	1.8	10
195	Established and emerging treatments for diabetes-associated lower urinary tract dysfunction. Naunyn-Schmiedeberg's Archives of Pharmacology, 2022, 395, 887-906.	3.0	10
196	Comparison of guineaâ€pig, bovine and rat Î±₁â€adrenoceptor subtypes. British Journal of Pharmacology, 1996, 117, 703-711.	5.4	9
197	Î²3-Adrenoceptors: a drug target in ophthalmology?. Naunyn-Schmiedeberg's Archives of Pharmacology, 2013, 386, 265-267.	3.0	9
198	Do Î²₃-adrenoceptor agonists cause urinary bladder smooth muscle relaxation by inhibiting acetylcholine release?. American Journal of Physiology - Renal Physiology, 2017, 313, F859-F861.	2.7	9

#	Article	IF	Citations
199	New Author Guidelines for Displaying Data and Reporting Data Analysis and Statistical Methods in Experimental Biology. Drug Metabolism and Disposition, 2020, 48, 64-74.	3.3	9
200	Possible mechanism of the negative inotropic effect of Î±1 -adrenoceptor agonists in rat isolated left atria after exposure to free radicals. British Journal of Pharmacology, 1998, 123, 952-958.	5.4	8
201	Can [125I]-Iodocyanopindolol Label Î²3-Adrenoceptors in Rat Urinary Bladder?. Frontiers in Pharmacology, 2010, 1, 128.	3.5	8
202	Muscarinic receptor subtype mRNA expression in the human prostate: association with age, pathological diagnosis, prostate size, or potentially interfering medications?. Naunyn-Schmiedeberg's Archives of Pharmacology, 2014, 387, 207-214.	3.0	8
203	Comparison of clot lysis activity and biochemical properties of originator tenecteplase (MetalyseÂ®) with those of an alleged biosimilar. Frontiers in Pharmacology, 2014, 5, 7.	3.5	8
204	Re: Tamsulosin and the Risk of Dementia in Older Men with Benign Prostatic Hyperplasia. European Urology, 2018, 74, 522-523.	1.9	8
205	Factors Associated With Nocturia-Related Quality of Life in Men With Lower Urinary Tract Symptoms and Treated With Tamsulosin Oral Controlled Absorption System in a Non-Interventional Study. Frontiers in Pharmacology, 2020, 11, 816.	3.5	8
206	Modelâ€based metaâ€analysis of the time to first acute urinary retention or benign prostatic hyperplasiaâ€related surgery in patients with moderate or severe symptoms. British Journal of Clinical Pharmacology, 2021, 87, 2777-2789.	2.4	8
207	Factors Associated with Decisions for Initial Dosing, Up-Titration of Propiverine and Treatment Outcomes in Overactive Bladder Syndrome Patients in a Non-Interventional Setting. Journal of Clinical Medicine, 2021, 10, 311.	2.4	8
208	Endothelin-induced inositol phosphate formation in rat kidney. Studies on receptor subtypes, G-proteins and regulation during ontogenesis. Naunyn-Schmiedeberg's Archives of Pharmacology, 1996, 354, 572-8.	3.0	7
209	An observational study of patient satisfaction with fesoterodine in the treatment of overactive bladder: effects of additional educational material. International Journal of Clinical Practice, 2014, 68, 1074-1080.	1.7	7
210	Desensitization of cAMP Accumulation via Human Î²3-Adrenoceptors Expressed in Human Embryonic Kidney Cells by Full, Partial, and Biased Agonists. Frontiers in Pharmacology, 2019, 10, 596.	3.5	7
211	Adrenoceptorsâ€"New roles for old players. British Journal of Pharmacology, 2019, 176, 2339-2342.	5.4	7
212	Building Robustness into Translational Research. Handbook of Experimental Pharmacology, 2019, 257, 163-175.	1.8	7
213	A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2020. Naunyn-Schmiedeberg's Archives of Pharmacology, 2021, 394, 839-852.	3.0	7
214	The Effect of Elective Sham Dose Escalation on the Placebo Response During an Antimuscarinic Trial for Overactive Bladder Symptoms. Journal of Urology, 2012, 187, 1721-1726.	0.4	6
215	How significant are your data? The need for a culture shift. Naunyn-Schmiedeberg's Archives of Pharmacology, 2014, 387, 1015-1016.	3.0	6
216	OnabotulinumtoxinA: How Deep Will It Go?. European Urology, 2014, 65, 1125-1127.	1.9	6

#	Article	IF	Citations
217	Synthesis and evaluation in rats of homologous series of [18F]-labeled dopamine D2/3 receptor agonists based on the 2-aminomethylchroman scaffold as potential PET tracers. EJNMMI Research, 2015, 5, 119.	2.5	6
218	Synthesis and Evaluation in Rats of the Dopamine D2/3 Receptor Agonist 18F-AMC20 as a Potential Radioligand for PET. Journal of Nuclear Medicine, 2015, 56, 133-139.	5.0	6
219	Î²-Adrenoceptor-mediated Relaxation of Urinary Bladder Muscle in Î²2-Adrenoceptor Knockout Mice. Frontiers in Pharmacology, 2016, 7, 118.	3.5	6
220	Protocol for a systematic review of guidelines for rigour in the design, conduct and analysis of biomedical experiments involving laboratory animals. BMJ Open Science, 2018, 2, e000004.	1.7	6
221	Expression and Signaling of Î²-Adrenoceptor Subtypes in the Diabetic Heart. Cells, 2020, 9, 2548.	4.1	6
222	Randomized, Placebo-Controlled, Double-Blind and Open-Label Studies in the Treatment and Prevention of Acute Diarrhea With Enterococcus faecium SF68. Frontiers in Medicine, 2020, 7, 276.	2.6	6
223	Adrenoceptors in GtoPdb v.2021.3. IUPHAR/BPS Guide To Pharmacology CITE, 2021, 2021, .	0.2	6
224	Saw palmetto extracts potently and noncompetitively inhibit human Î±1â€adrenoceptors in vitro. Prostate, 1999, 38, 208-215.	2.3	6
225	Bradykinin may be involved in neuropeptide Y-induced diuresis, natriuresis, and calciuresis. American Journal of Physiology - Renal Physiology, 1998, 275, F502-F509.	2.7	5
226	Re: Tatemichi S, Tomiyama Y, Maruyama I, Kobayashi S, Kobayashi K, Maezawa A, Kobayashi M, Yamazaki Y, Shibata N. 2006. Uroselectivity in male dogs of silodosin (KMD-3213), a novel drug for the obstructive component of benign prostatic hyperplasia. Neurourol Urodynam 25:792â€“799.. Neurourology and Urodynamics, 2006, 25, 800-801.	1.5	5
227	Observational study on safety and tolerability of duloxetine in the treatment of female stress urinary incontinence in <scp>G</scp>erman routine practice. British Journal of Clinical Pharmacology, 2013, 75, 1098-1108.	2.4	5
228	Cross-regulation between cardiac muscarinic acetylcholine receptors and Î²-adrenoceptors: lessons for use of knock-out mice. Naunyn-Schmiedeberg's Archives of Pharmacology, 2013, 386, 1-3.	3.0	5
229	Do review articles boost journal impact factors? A longitudinal analysis for five pharmacology journals. Naunyn-Schmiedeberg's Archives of Pharmacology, 2018, 391, 1033-1035.	3.0	5
230	Why Are New Drugs Expensive and How Can They Stay Affordable?. Handbook of Experimental Pharmacology, 2019, 260, 453-466.	1.8	5
231	Upregulation of Î²3-adrenoceptorsâ€”a general marker of and protective mechanism against hypoxia?. Naunyn-Schmiedeberg's Archives of Pharmacology, 2020, 393, 141-146.	3.0	5
232	Validation of Fenoterol to Study Î²₂-Adrenoceptor Function in the Rat Urinary Bladder. Pharmacology, 2022, 107, 116-121.	2.2	5
233	What Are Realistic Expectations to Become Free of Overactive Bladder Symptoms? Experience from Non-interventional Studies with Propiverine. Advances in Therapy, 2022, 39, 2489-2501.	2.9	5
234	Agonist signalling properties of radiotracers used for imaging of dopamine D2/3 receptors. EJNMMI Research, 2014, 4, 53.	2.5	4

#	Article	IF	Citations
235	Expectations and satisfaction of academic investigators in nonclinical collaboration with the pharmaceutical industry. Naunyn-Schmiedeberg's Archives of Pharmacology, 2015, 388, 613-622.	3.0	4
236	Preclinical research strategies for newly approved drugs as reflected in early publication patterns. Naunyn-Schmiedeberg's Archives of Pharmacology, 2016, 389, 187-199.	3.0	4
237	Longitudinal trends and subgroup analysis in publication patterns for preclinical data of newly approved drugs. Naunyn-Schmiedeberg's Archives of Pharmacology, 2016, 389, 201-209.	3.0	4
238	Treatment of Bladder Pain Syndrome: One Size May Not Fit All. European Urology, 2018, 74, 631-632.	1.9	4
239	Impact of the Neck and/or Shoulder Pain on Self-reported Headache Treatment Responses â€“ Results From a Pharmacy-Based Patient Survey. Frontiers in Neurology, 0, 13, .	2.4	4
240	Pathophysiological Factors in the Relationship between Chronological Age and Calculated Lung Age as Detected in a Screening Setting in Community-Dwelling Subjects. Frontiers in Medicine, 2016, 3, 2.	2.6	3
241	Cellular basis of detrusor smooth muscle contraction. BJU International, 2016, 117, 177-178.	2.5	3
242	Revised editorial guidelines for manuscripts on the pharmacology of plant extracts. Naunyn-Schmiedeberg's Archives of Pharmacology, 2017, 390, 765-766.	3.0	3
243	Pharmacokinetics of Ambroxol Sustained Release (MucosolvanÂ® Retard) Compared with Other Formulations in Healthy Volunteers. Pulmonary Therapy, 2020, 6, 119-130.	2.2	3
244	Impact of guideline awareness in public pharmacies on counseling of patients with acute or chronic constipation in a survey of pharmacy personnel. BMC Gastroenterology, 2020, 20, 191.	2.0	3
245	Statistical inference in abstracts of 3 influential clinical pharmacology journals analysed using a textâ€mining algorithm. British Journal of Clinical Pharmacology, 2021, 87, 4173-4182.	2.4	3
246	Study Designs for Evaluation of Combination Treatment: Focus on Individual Patient Benefit. Biomedicines, 2022, 10, 270.	3.2	3
247	Associations between the Patient Perception of Bladder Condition score and overactive bladder syndrome symptoms at baseline and upon treatment. Neurourology and Urodynamics, 2022, 41, 1399-1405.	1.5	3
248	Experimental and clinical nephroprotection by the xanthine oxidase inhibitor febuxostat. Naunyn-Schmiedeberg's Archives of Pharmacology, 2016, 389, 815-817.	3.0	2
249	Re: A Randomized Controlled Study of the Efficacy of Tamsulosin Monotherapy and its Combination with Mirabegron for Overactive Bladder Induced by Benign Prostatic Obstruction. European Urology, 2016, 69, 174.	1.9	2
250	Denominator changes may obscure results from single-well assays: Î²3-adrenoceptor ligand-induced changes of cell number as example. Naunyn-Schmiedeberg's Archives of Pharmacology, 2017, 390, 761-763.	3.0	2
251	Perspectives of Pharmacology over the Past 100 Years. Handbook of Experimental Pharmacology, 2019, 260, 3-16.	1.8	2
252	Choice of y-axis can mislead readers. Naunyn-Schmiedeberg's Archives of Pharmacology, 2020, 393, 1769-1772.	3.0	2

#	Article	IF	Citations
253	Function and morphology of the urinary bladder after denervation. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2021, 320, R833-R834.	1.8	2
254	Use of Antibodies in the Research on Muscarinic Receptor Subtypes. Neuromethods, 2016, , 83-94.	0.3	2
255	Neuropeptide Y receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide To Pharmacology CITE, 2019, 2019, .	0.2	2
256	Agonistâ€induced desensitization of rat bladder relaxation by Î²â€adrenergic agonists. FASEB Journal, 2008, 22, 916.5.	0.5	2
257	Although the phosphodiesterase inhibitors have revolutionised the treatment of ED, postoperative ED due to nerve damage remains a therapeutic challenge. European Urology, 2007, 52, 580-1.	1.9	2
258	Transient receptor potential (TRP) channels as drug targets. Naunyn-Schmiedeberg's Archives of Pharmacology, 2006, 373, 271-272.	3.0	1
259	Publication trends in Naunyn-Schmiedebergâ€™s Archives of Pharmacology: focus on pharmacology in Egypt. Naunyn-Schmiedeberg's Archives of Pharmacology, 2013, 386, 929-933.	3.0	1
260	Editorial Comment. Journal of Urology, 2016, 196, 1808-1808.	0.4	1
261	Re: The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. European Urology, 2017, 71, 834-835.	1.9	1
262	Is Dipstick Urinalysis Screening Beneficial in Men with Lower Urinary Tract Symptoms?. Advances in Therapy, 2019, 36, 2954-2967.	2.9	1
263	Editorial: G Protein-Coupled Receptor Kinases (GRKs) and Î²-Arrestins: New Insights Into Disease Regulators. Frontiers in Pharmacology, 2020, 10, 1654.	3.5	1
264	A teaching tool about the fickle p value and other statistical principles based on real-life data. Naunyn-Schmiedeberg's Archives of Pharmacology, 2021, 394, 1315-1319.	3.0	1
265	Effects of Nifedipine on Renal and Cardiovascular Responses to Neuropeptide Y in Anesthetized Rats. Molecules, 2021, 26, 4460.	3.8	1
266	Reproducibility of preclinical data: one man's poison is another man's meat. Advances in Precision Medicine, 2016, 1, .	0.3	1
267	Î² 3 â€Adrenergic receptor gene polymorphisms: comparison of human with chimpanzee and Rhesus macaque. FASEB Journal, 2008, 22, 1134.3.	0.5	1
268	Gene expression profiling of Gâ€protein coupled receptors in human urothelial cell lines. FASEB Journal, 2010, 24, 773.13.	0.5	1
269	Does coupling to ADP ribosylation factor 6 explain differences between muscarinic and other receptors in interaction with Î²-adrenoceptor-mediated smooth muscle relaxation?. Naunyn-Schmiedeberg's Archives of Pharmacology, 2022, 395, 381-386.	3.0	1
270	An anthology from Naunyn-Schmiedebergâ€™s Archives of Pharmacology. Naunyn-Schmiedeberg's Archives of Pharmacology, 2006, 373, 139-139.	3.0	0

#	Article	IF	Citations
271	Is antimuscarinic treatment of overactive bladder symptoms effective and safe in elderly patients?. Aging Health, 2010, 6, 595-597.	0.3	0
272	Reply. BJU International, 2010, 105, 1017-1018.	2.5	0
273	An invitation for comprehensive single-compound reviews on the pharmacological properties of newly launched drugs. Naunyn-Schmiedeberg's Archives of Pharmacology, 2013, 386, 1019-1020.	3.0	0
274	Editorial Comment from <scp>D</scp>r <scp>M</scp>ichel to Expression and functional role of Î²₃â€adrenoceptors in the human ureter. International Journal of Urology, 2013, 20, 1015-1015.	1.0	0
275	Ex Vivo Characterization of a Novel Iodine-123-Labelled Aminomethylchroman as a Potential Agonist Ligand for SPECT Imaging of Dopamine D2/3 Receptors. International Journal of Molecular Imaging, 2014, 2014, 1-10.	1.3	0
276	Hope for Disease-Modifying Treatment of Systemic Sclerosis/Scleroderma. Journal of Pharmacology and Experimental Therapeutics, 2014, 350, 480-482.	2.5	0
277	How much potential for transient receptor potential channels in the bladder?. BJU International, 2015, 115, 350-351.	2.5	0
278	Sa1790 Comparative Clinical Studies Between Racecadotril and Loperamide or Saccharomyces Boulardii in Adult Patients With Acute Diarrhea. Gastroenterology, 2015, 148, S-333.	1.3	0
279	Impact of Formulation on the Pharmacokinetic Profile of Dutasteride. Clinical Drug Investigation, 2016, 36, 769-770.	2.2	0
280	Editorial on â€œBetaâ€3 adrenergic receptor is expressed in acetylcholineâ€containing nerve fibers of the human urinary bladder: An immunohistochemical studyâ€. Neurourology and Urodynamics, 2017, 36, 2192-2192.	1.5	0
281	EDITORIAL COMMENT. Urology, 2020, 137, 6.	1.0	0
282	Die Reproduzierbarkeitskrise: Bedrohung oder Chance fÃ¼r die Wissenschaft?. Biologie in Unserer Zeit, 2020, 50, 79-79.	0.2	0
283	Medications and Drug Targets for the Treatment of Diseases of the Urinary Bladder and Urethra. , 2021, , .		0
284	Editorial Comment. Journal of Urology, 2021, 205, 1131-1131.	0.4	0
285	Re: PIEZO2 in Sensory Neurons and Urothelial Cells Coordinate Urination. European Urology, 2021, 80, 255-256.	1.9	0
286	Septic shock: A role for RGS proteins?. FASEB Journal, 2008, 22, 907.10.	0.5	0
287	Inhibition of sphingosine kinase induces vasoconstriction in isolated carotid arteries obtained from spontaneous hypertensive but not normotensive rats. FASEB Journal, 2008, 22, 1128.8.	0.5	0
288	Mechanisms of nerve growth factor release from a human urothelial cell line. FASEB Journal, 2011, 25, 1020.5.	0.5	0

#	Article	IF	Citations
289	What Do Academic Investigators Want and Get from Preclinical Collaboration with the Pharmaceutical Industry?. FASEB Journal, 2015, 29, 928.10.	0.5	0
290	Trust me â€“ Iâ€™m a scientist. , 2016, , 33-35.		0
291	PD33-02â€ƒIMPACT OF EARLY VS. DELAYED INITIATION OF DUTASTERIDE/TAMSULOSIN COMBINATION THERAPY IN LOWER URINARY TRACT SYMPTOMS/BENIGN PROSTATIC HYPERPLASIA (LUTS/BPH) PATIENTS WITH MODERATE TO SEVERE SYMPTOMS AT RISK FOR PROGRESSION. Journal of Urology, 2020, 203, e704-e705.	0.4	0
292	Editorial Comment. Journal of Urology, 2020, 204, 324-324.	0.4	0
293	Bladder Enlargement Correlates with Plasma Insulin, Not Glucose Levels in Fructoseâ€Fed Rats. FASEB Journal, 2020, 34, 1-1.	0.5	0
294	Cardiovascular, Urinary and Respiratory Pharmacology: Overview. , 2021, , .		0
295	Î²-Adrenoceptor Antagonists. , 2021, , .		0